Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome in nude mice bearing human melanomas G361 and SEKI

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 4091-4097

  Kawamura, Ikuo ^a   Lacey, Elizabeth ^a   Inami, Masamichi ^a   Nishigaki, Fusako ^a   Naoe, Yoshinori ^a   Tsujimoto, Susumu ^a   Manda, Toshitaka ^a   Goto, Toshio ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cachexia; G361; LPL; Ponalrestat; SEKI

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; PONALRESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; BODY MASS; CACHEXIA; CONTROLLED STUDY; DRUG EFFICACY; EPIDIDYMIS FAT; GASTROCNEMIUS MUSCLE; HUMAN; HUMAN CELL; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; WEIGHT REDUCTION;

ALDEHYDE REDUCTASE; ANIMALS; BODY WEIGHT; CACHEXIA; EATING; ENZYME INHIBITORS; EPIDIDYMIS; GROWTH INHIBITORS; HUMANS; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; LYMPHOKINES; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MUSCLE, SKELETAL; NEOPLASM TRANSPLANTATION; PHTHALAZINES; TIME FACTORS;

EID: 0032806466     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. DeWys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Engstrom PF, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW and Tormey DC: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69: 491-497, 1980.
2. Kern KA and Norton JA: Cancer cachexia. J Parenteral Enteral Nutr 12: 286-298, 1988.
3. Curtis EB, Krech R and Walsh TD: Common symptoms in patients with advanced cancer. J Palliat Care 7: 25-29, 1991.
4. Lazo PA: Tumor-host metabolic interaction and cachexia. FEBS Lett 187: 189-192, 1985.
5. Legaspi A, Jeevanandam M, Starnes HF Jr. and Brennan MF: Whole body lipid and energy metabolism in the cancer patient. Metabolism 36: 958-963, 1987.
6. Mulligan HD, Beck SA and Tisdale MJ: Lipid metabolism in cancer cachexia. Br J Cancer 66: 57-61, 1992.
7. Vlassara H, Spiegel RJ, Doval DS and Cerami A: Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm Metabol Res 18: 698-703, 1986.
8. Noguchi Y, Vydelingum NA, Younes RN, Fried SK and Brennan MF: Tumor-induced alterations in tissue lipoprotein lipase activity and mRNA levels. Cancer Res 51: 863-869, 1991.
9. Kawamura I, Yamamoto N, Sakai F, Yamazaki H, Naoe Y, Inami M, Manda T and Shimomura K: Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor. Anticancer Res 19: 341-348, 1999.
10. Kondo Y, Ueyama Y and Ohsawa N: Cachexia in nude bearing a human malignant melanoma. In: Proceedings of the second international workshop on nude mice (Nomura T, Ohsawa N, Tamaoki N and Fujiwara K, eds). Tokyo, University of Tokyo Press, 1977, pp 441-448.
11. Mori M, Yamaguchi K and Abe K: Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem Biophys Res Commun 160: 1085-1092, 1989.
12. Mori M, Yamaguchi K, Honda S, Nagasaki K, Ueda M, Abe O and Abe K: Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51: 6656-6659, 1991.
13. Iseki H, Kajimura N, Ohue C, Tanaka R, Akiyama Y and Yamaguchi K: Cytokine production in five tumor cell lines with activity to induce cancer cachexia syndrome in nude mice. Jpn J Cancer Res 86: 562-567, 1995.
14. Kajimura N, Iseki H, Tanaka R, Ohue C, Otsubo K, Gyoutoku M, Sasaki K, Akiyama Y and Yamaguchi K: Toxohormones responsible for cancer cachexia syndrome in nude mice bearing human cancer cell lines. Cancer Chemother Pharmocal 38: S48-S52, 1996.
15. Metcalf D, Nicola NA and Gearing DP: Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 76: 50-56, 1990.
16. Kawakami M, Kondo Y, Imai Y, Hashiguchi M, Ogawa H, Hiragun A, Aotsuka S Shibata S, Oda T, Murase T and Takaku F: Suppression of lipoprotein lipase in 3T3-L1 cells by a mediator produced by SEKI melanoma, a cachexia-inducing human melanoma cell line. J Biochem 109: 78-82, 1991.
17. Tisdale MJ: Biology of cachexia. J Natl Cancer Inst 89: 1763-1773, 1997.
18. Stribling D, Mirrlees DJ, Harrison HE and Earl DCN: Properties of ICI 128, 436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat. Metabolism 34: 336-344, 1985.
19. Baumann H and Wong GG: Hepatocyte-stimulating factor III shares structural and functional identity with leukemia-inhibitory factor. J Immunol 143: 1163-1167, 1989.
20. Marinkovic S, Jahreis GP, Wong GG and Baumann H: IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo. J Immunol 142: 808-812, 1989.
21. Metcalf D: Leukemia inhibitory factor - a puzzling polyfunctional regulator. Growth Fact 7: 169-173, 1992.
22. Alexander HR, Billingsley KG, Block MI and Fraker DL: D-factor/ leukemia inhibitory factor: evidence for its role as mediator in acute and chronic inflammatory disease. Cytokine 6: 589-596, 1994.